597 related articles for article (PubMed ID: 7814643)
1. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
[TBL] [Abstract][Full Text] [Related]
4. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
5. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
6. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
[TBL] [Abstract][Full Text] [Related]
7. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
8. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors.
Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F
Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376
[TBL] [Abstract][Full Text] [Related]
9. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
11. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
12. Umami receptor activation increases duodenal bicarbonate secretion via glucagon-like peptide-2 release in rats.
Wang JH; Inoue T; Higashiyama M; Guth PH; Engel E; Kaunitz JD; Akiba Y
J Pharmacol Exp Ther; 2011 Nov; 339(2):464-73. PubMed ID: 21846840
[TBL] [Abstract][Full Text] [Related]
13. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
14. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
16. Effect of GIP and GLP-1 antagonists on insulin release in the rat.
Tseng CC; Zhang XY; Wolfe MM
Am J Physiol; 1999 Jun; 276(6):E1049-54. PubMed ID: 10362617
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells.
Moens K; Berger V; Ahn JM; Van Schravendijk C; Hruby VJ; Pipeleers D; Schuit F
Diabetes; 2002 Mar; 51(3):669-75. PubMed ID: 11872665
[TBL] [Abstract][Full Text] [Related]
18. Interaction of glucagon-like peptide-1(7-36) amide and gastric inhibitory polypeptide or cholecystokinin on insulin and glucagon secretion from the isolated perfused rat pancreas.
Suzuki S; Kawai K; Ohashi S; Watanabe Y; Yamashita K
Metabolism; 1992 Apr; 41(4):359-63. PubMed ID: 1556941
[TBL] [Abstract][Full Text] [Related]
19. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
D'Alessio DA; Vogel R; Prigeon R; Laschansky E; Koerker D; Eng J; Ensinck JW
J Clin Invest; 1996 Jan; 97(1):133-8. PubMed ID: 8550824
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]